FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892869908> ?p ?o ?g. }

• W2892869908 endingPage "5191" @default.
• W2892869908 startingPage "5183" @default.
• W2892869908 abstract "We designed and evaluated a novel albumin-binder-conjugated 177Lu-PSMA-617 derivative, 177Lu-HTK01169, with an extended blood retention time to maximize the radiation dose delivered to prostate tumors expressing prostate-specific membrane antigen (PSMA). PSMA-617 and HTK01169 that contained N-[4-(p-iodophenyl)butanoyl]-Glu as an albumin-binding motif were synthesized using the solid-phase approach. Binding affinity to PSMA was determined by in vitro competition-binding assay. 177Lu labeling was performed in acetate buffer (pH 4.5) at 90 °C for 15 min. SPECT/CT imaging, biodistribution, and endoradiotherapy studies were conducted in mice bearing PSMA-expressing LNCaP tumor xenografts. Radiation dosimetry was calculated using OLINDA software. Lu-PSMA-617 and Lu-HTK01169-bound PSMA with high affinity (Ki values = 0.24 and 0.04 nM, respectively). SPECT imaging and biodistribution studies showed that 177Lu-PSMA-617 and 177Lu-HTK01169 were excreted mainly via the renal pathway. With fast blood clearance (0.68%ID/g at 1 h postinjection), the tumor uptake of 177Lu-PSMA-617 peaked at 1 h postinjection (15.1%ID/g) and gradually decreased to 7.91%ID/g at 120 h postinjection. With extended blood retention (16.6 and 2.10%ID/g at 1 and 24 h, respectively), the tumor uptake of 177Lu-HTK01169 peaked at 24 h postinjection (55.9%ID/g) and remained at the same level by the end of the study (120 h). Based on dosimetry calculations, 177Lu-HTK01169 delivered an 8.3-fold higher radiation dose than 177Lu-PSMA-617 to LNCaP tumor xenografts. For the endoradiotherapy study, the mice treated with 177Lu-PSMA-617 (18.5 MBq) all reached humane end point (tumor volume >1000 mm3) by Day 73 with a median survival of 58 days. Mice treated with 18.5, 9.3, 4.6, or 2.3 MBq of 177Lu-HTK01169 had a median survival of >120, 103, 61, and 28 days, respectively. With greatly enhanced tumor uptake and treatment efficacy compared to 177Lu-PSMA-617 in preclinical studies, 177Lu-HTK01169 warrants further investigation for endoradiotherapy of prostate cancer." @default.
• W2892869908 created "2018-10-05" @default.
• W2892869908 creator A5006978008 @default.
• W2892869908 creator A5022775390 @default.
• W2892869908 creator A5040772609 @default.
• W2892869908 creator A5043365724 @default.
• W2892869908 creator A5049964502 @default.
• W2892869908 creator A5053640698 @default.
• W2892869908 creator A5058706376 @default.
• W2892869908 creator A5071598124 @default.
• W2892869908 creator A5077969822 @default.
• W2892869908 date "2018-09-25" @default.
• W2892869908 modified "2023-10-06" @default.
• W2892869908 title "Enhancing Treatment Efficacy of ¹⁷⁷Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies" @default.
• W2892869908 cites W1977316337 @default.
• W2892869908 cites W2011660334 @default.
• W2892869908 cites W2030940240 @default.
• W2892869908 cites W2063649715 @default.
• W2892869908 cites W2071761375 @default.
• W2892869908 cites W2091602327 @default.
• W2892869908 cites W2112451160 @default.
• W2892869908 cites W2112979860 @default.
• W2892869908 cites W2160881737 @default.
• W2892869908 cites W2237082602 @default.
• W2892869908 cites W2287576637 @default.
• W2892869908 cites W2304896218 @default.
• W2892869908 cites W2341926107 @default.
• W2892869908 cites W2343936933 @default.
• W2892869908 cites W2397136240 @default.
• W2892869908 cites W2467018059 @default.
• W2892869908 cites W2469717780 @default.
• W2892869908 cites W2481498506 @default.
• W2892869908 cites W2518199070 @default.
• W2892869908 cites W2523333323 @default.
• W2892869908 cites W2532226140 @default.
• W2892869908 cites W2593925322 @default.
• W2892869908 cites W2606187374 @default.
• W2892869908 cites W2610081635 @default.
• W2892869908 cites W2611673620 @default.
• W2892869908 cites W2612027160 @default.
• W2892869908 cites W2622153869 @default.
• W2892869908 cites W2625296464 @default.
• W2892869908 cites W2743828160 @default.
• W2892869908 cites W2786988345 @default.
• W2892869908 cites W2795555192 @default.
• W2892869908 cites W2799487694 @default.
• W2892869908 cites W2799931007 @default.
• W2892869908 cites W2805198925 @default.
• W2892869908 cites W2808022995 @default.
• W2892869908 cites W2808774793 @default.
• W2892869908 cites W2887229904 @default.
• W2892869908 doi "https://doi.org/10.1021/acs.molpharmaceut.8b00720" @default.
• W2892869908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30251544" @default.
• W2892869908 hasPublicationYear "2018" @default.
• W2892869908 type Work @default.
• W2892869908 sameAs 2892869908 @default.
• W2892869908 citedByCount "68" @default.
• W2892869908 countsByYear W28928699082019 @default.
• W2892869908 countsByYear W28928699082020 @default.
• W2892869908 countsByYear W28928699082021 @default.
• W2892869908 countsByYear W28928699082022 @default.
• W2892869908 countsByYear W28928699082023 @default.
• W2892869908 crossrefType "journal-article" @default.
• W2892869908 hasAuthorship W2892869908A5006978008 @default.
• W2892869908 hasAuthorship W2892869908A5022775390 @default.
• W2892869908 hasAuthorship W2892869908A5040772609 @default.
• W2892869908 hasAuthorship W2892869908A5043365724 @default.
• W2892869908 hasAuthorship W2892869908A5049964502 @default.
• W2892869908 hasAuthorship W2892869908A5053640698 @default.
• W2892869908 hasAuthorship W2892869908A5058706376 @default.
• W2892869908 hasAuthorship W2892869908A5071598124 @default.
• W2892869908 hasAuthorship W2892869908A5077969822 @default.
• W2892869908 hasConcept C121608353 @default.
• W2892869908 hasConcept C126322002 @default.
• W2892869908 hasConcept C185592680 @default.
• W2892869908 hasConcept C202751555 @default.
• W2892869908 hasConcept C2777807558 @default.
• W2892869908 hasConcept C2779723316 @default.
• W2892869908 hasConcept C2780192828 @default.
• W2892869908 hasConcept C2989005 @default.
• W2892869908 hasConcept C2993559085 @default.
• W2892869908 hasConcept C502942594 @default.
• W2892869908 hasConcept C55493867 @default.
• W2892869908 hasConcept C71924100 @default.
• W2892869908 hasConcept C75088862 @default.
• W2892869908 hasConceptScore W2892869908C121608353 @default.
• W2892869908 hasConceptScore W2892869908C126322002 @default.
• W2892869908 hasConceptScore W2892869908C185592680 @default.
• W2892869908 hasConceptScore W2892869908C202751555 @default.
• W2892869908 hasConceptScore W2892869908C2777807558 @default.
• W2892869908 hasConceptScore W2892869908C2779723316 @default.
• W2892869908 hasConceptScore W2892869908C2780192828 @default.
• W2892869908 hasConceptScore W2892869908C2989005 @default.
• W2892869908 hasConceptScore W2892869908C2993559085 @default.
• W2892869908 hasConceptScore W2892869908C502942594 @default.
• W2892869908 hasConceptScore W2892869908C55493867 @default.
• W2892869908 hasConceptScore W2892869908C71924100 @default.
• W2892869908 hasConceptScore W2892869908C75088862 @default.

• next